

Increased levels of circulating neurotoxic metabolites in patients with mild Covid19

Estibaliz Santiago-Mujika¹, Kevin Heinrich², Sonia George¹, Colt D Capan¹, Cameron Forton¹, Zachary Madaj³ Amanda R Burmeister¹, Matthew Sims^{4,5,6}, J Andrew Pospisilik¹, Patrik Brundin¹, Stewart F Graham^{7,8}, and Lena Brundin^{1,9}

¹ Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI 49503, USA.

² Quire Inc., Memphis, TN 38103, USA

³ Bioinformatics & Biostatistics core, Van Andel Institute, Grand Rapids, MI 49503, USA

⁴ Section of Infectious Diseases and International Medicine, Department of Internal Medicine, Beaumont Health, Royal Oak, Michigan 48073, USA

⁵ Department of Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.

⁶ Department of Internal Medicine, Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.

⁷ Metabolomics Department, Beaumont Research Institute, Beaumont Health, Royal Oak, Michigan 48073, USA.

⁸ Oakland University-William Beaumont School of Medicine, Rochester, MI 48309, USA.

⁹ Department of Psychiatry, Michigan State University College of Human Medicine, Grand Rapids, MI 49503, USA.

Corresponding author, Lena.Brundin@vai.org, Van Andel Institute, 333 Bostwick Ave NE, Grand Rapids, MI 49503, USA.

38 **Abstract**

39
40 SARS-CoV-2 corona virus causes a multi-faceted and poorly defined clinical and
41 pathological phenotype involving hyperinflammation, cytokine release, and long-term
42 cognitive deficits, with an undefined neuropathological mechanism. Inflammation
43 increases the activity of the kynurenine pathway, which is linked to neurodegenerative
44 and psychiatric disorders. We sought to determine whether the kynurenine pathway is
45 impacted in patients with mild COVID-19, leading to elevated neurotoxic metabolites in
46 blood, and whether such changes are associated with pro-inflammatory cytokines. Serum
47 samples were taken from 150 patients and analyzed by ELISA and ultra-high
48 performance liquid chromatography (UHPLC). The data were analyzed using multiple
49 linear regression models adjusted for age and sex. We found increased levels of
50 kynurenine, quinolinic acid and 3-hydroxykynurenine in serum from patients with mild
51 COVID-19, together with increased levels of IL-6, ICAM-1, VCAM-1 and neopterin. The
52 levels of neurotoxic metabolites were significantly associated with key inflammatory
53 cytokines including IL-6 and TNF α . The COVID-19 risk-factor hypertension was
54 associated with the highest levels of neurotoxic metabolites in plasma. These neuroactive
55 metabolites could be part of the pathological mechanisms underlying cognitive
56 impairment during and post-COVID and should be explored as potential biomarkers for
57 long-COVID symptoms.

58

59 **Keywords:** Mild COVID-19, Tryptophan metabolism, 3-HK, quinolinic acid

60 **Introduction**

61 COVID-19, caused by SARS-CoV-2, can lead to systemic disease, including pneumonia,
62 acute respiratory distress syndrome, and impaired consciousness (1). COVID-19 also
63 leads to an activation of innate and adaptive immune responses which result in a
64 substantial inflammatory response (2). In a certain percentage of patients, symptoms
65 persist over time with the potential of symptoms lasting months and up to years after initial
66 illness. In these patients, there is a predominance for those effected by the illness to
67 present neuropsychiatric symptoms (3). Recent studies have shown an increased risk for
68 acute and long-term sequelae after COVID-19 in both vaccinated and unvaccinated
69 patients (4). However, there is currently a lack of understanding for the factors that drive
70 the neuropsychiatric symptoms present during acute and long-term COVID-19. Thus,
71 there is an urgent need to identify biomarkers that can indicate the disease progression
72 during long-COVID, as well as contribute to the understanding of its underlying pathology.

73
74 The kynurenine pathway is the major route for tryptophan (TRP) metabolism, and it
75 contributes to several fundamental biological processes, all converging in energy
76 metabolism. Infections and inflammatory conditions can alter the activity of the enzymes
77 in this pathway (5). Several neuroactive metabolites of the kynurenine pathway that bind
78 neuronal receptors have an underlying role in both neurological and psychiatric symptoms
79 (5). As such, quinolinic acid (QUIN) is an agonist of the glutamatergic *N*-methyl-D-
80 aspartate (NMDA) receptor and kynurenic acid (KYNA) is an antagonist of the same
81 receptor (6). In high concentrations, QUIN induces excitotoxic neuronal death by allowing
82 excessive amounts of calcium to enter the cell (6). While KYNA blocks the cholinergic $\alpha 7$

83 nicotinic receptor, it also antagonizes the glycine site of the NMDA-receptor, thus
84 preventing calcium influx (7, 8).

85

86 Another kynurenine pathway metabolite, 3-hydroxykynurenine (3-HK) is also neurotoxic
87 and pro-inflammatory (9). 3-HK promotes reactive oxygen species (ROS) generation
88 through several oxidative conversions (10), and 3-HK can accelerate endothelial cell
89 apoptosis (11). The neurotoxic effects of QUIN and 3-HK are additive (5). Entry of QUIN
90 and KYNA into the central nervous system (CNS) is likely partially prohibited by an intact
91 blood brain barrier (BBB). KYN (the metabolite produced from TRP metabolism) and 3-
92 HK, can freely pass the BBB (12). Within the brain, KYN is metabolized to KYNA by
93 astrocytes (5, 13), or to 3-HK and then further to QUIN by microglia and macrophages (5,
94 14). SARS-CoV-2 infection is known to affect the KYN levels by inducing the production
95 of the pro-inflammatory cytokine, interferon-gamma (IFN- γ) that stimulates the rate-
96 limiting enzyme in the kynurenine pathway, indoleamine-2,3-dioxygenase (IDO), thus
97 affecting KYN levels (15).

98 As previously mentioned, SARS-CoV-2 can lead to a substantial inflammatory response,
99 which affects the levels of different metabolites from the kynurenine pathway. However,
100 there are also other proteins involved in the inflammatory response, such as the
101 intercellular cell adhesion molecule-1 (ICAM-1) and the vascular cell adhesion protein-1
102 (VCAM-1), in which we were interested. Both ICAM-1 and VCAM-1 are cell surface
103 glycoproteins that govern immune cell migration to sites of inflammation and T-cell-
104 mediated immunity in tissues (16-18). They are expressed in vascular endothelial cells
105 and in response to inflammation, their expression is induced in epithelial and immune

106 cells (19, 20). ICAM-1 and VCAM-1 play a central role in leukocyte trafficking, lymphocyte
107 activation and several immune responses, and the upregulation of ICAM-1 is a signature
108 event during inflammation (21). A recent study showed that monocyte-derived
109 macrophages drive the inflammatory response to SARS-CoV-2 and long-term changes
110 in inflammatory response of monocytes can be detected in convalescent SARS-CoV-2
111 patients following mild infection (22). Therefore, it is of interest to determine whether the
112 levels of ICAM-1 and VCAM-1 are affected in patients with mild COVID-19, and whether
113 they are linked to kynurenine pathway activation.

114 In the current study, we analyzed serum samples from 150 patients, 44 of whom tested
115 positive for COVID-19 but exhibited mild disease and were non-hospitalized. We sought
116 to determine whether the production of neuroactive and neurotoxic metabolites along the
117 kynurenine pathway, as well as several proteins involved in inflammation, is altered in
118 patients with mild COVID-19, as this could be associated to the underlying
119 neuropsychiatry symptoms. Kynurenine pathway metabolites are correlated with the
120 severity and predicted negative outcomes of symptoms in COVID-19 patients; and could
121 potentially serve as biomarkers or predictors of neuropsychiatric long-covid symptoms.

122

123 **Results**

124

125 ***Demographics of study participants***

126 Serum samples were taken from 150 individuals, 44 were diagnosed with mild COVID-19
127 (defined for this purpose as positive, but not requiring hospitalization or treatment) and
128 106 were controls who tested negative for COVID-19. Demographics of study participants
129 are shown in **Table 1**. The average age of SARS-CoV-2 positive individuals was $44.2 \pm$
130 13.1 years and controls were 45.6 ± 13.4 years. 47 females (44.3%) were included as
131 controls and 25 females (56.8%) were enrolled with mild COVID-19. Of all participants, 8
132 controls (7.5%) and 7 COVID +ve (15.9%) were Asian, 5 controls (4.7%) and 0 COVID
133 +ve (0%) were Black/African, 84 controls (79.2%) and 35 COVID +ve (79.5%) were
134 White/Caucasian, 4 controls (3.8%) and 2 COVID +ve (4.5%) were Other, and 5 control
135 (4.7%) and 0 COVID +ve (0%) opted to not answer.

136 ***Higher levels of IL-6 present in patients with mild COVID-19***

137 Individuals with mild COVID-19 demonstrated significantly higher levels of IL-6 when
138 compared to negative controls (ANOVA F: 5.260, $p= 0.0028^{**}$) (**Figure 1a**). TNF- α levels
139 were not altered when both groups were compared (ANOVA F: 2.347, $p= 0.075$ ns)
140 (**Figure 1b**). No significant differences were observed for the other inflammatory markers
141 including IL-13 (F: 1.847, $p= 0.141$ ns), IL-8 (F: 1.223, $p= 0.304$ ns), IFN- γ (F: 2.054, $p=$
142 0.109 ns, data not shown). All data was corrected for age and sex.

143

144 ***Higher levels of several proteins related to inflammation present in patients with***
145 ***mild COVID-19***

146 The level of ICAM-1 was increased in patients who tested positive for COVID-19 when
147 compared to the ones that did not (data corrected for sex and age, ANOVA test F: 5.823,
148 $p < 0.001$ ***) (**Figure 2a**). Similarly, patients positive for COVID-19 also showed increased
149 levels of VCAM-1 when compared to the PCR-negative patients (data adjusted for sex
150 and age, ANOVA F: 3.307, $p = 0.022$ *). The inflammatory related protein, neopterin was
151 also increased in COVID-19 positive patients (data adjusted for age and sex, ANOVA test
152 F: 3.309, $p = 0.022$ *) (**Figure 2b and 2c**)

153 ***Metabolites of the kynurenine pathway are increased in patients with mild COVID-***
154 ***19***

155 Previous research demonstrated alterations in kynurenine pathway activity following
156 infection (23-25). Therefore, we investigated alterations in kynurenine pathway
157 metabolite levels. Kynurenine (KYN), the first metabolite of the pathway, was significantly
158 increased in patients with mild COVID-19 when compared to patients who tested negative
159 for SARS-CoV-2 (ANOVA test F: 11.195, $p = 0 < 0.001$ ***, **Figure 3**). Additionally, 3-HK
160 and QUIN, were increased in patients who tested positive for COVID-19 when compared
161 to patients who did not (ANOVA test F: 3.990, $p = 0.009$ **; F: 8.492, $p < 0.001$ ***,
162 respectively, **Figure 3**). Further, picolinic acid (PIC) levels in COVID-19 positive patients
163 were significantly decreased when compared to COVID negative patients (ANOVA test
164 F: 4.399, $p = 0.005$ **). Finally, anthranilic acid (AA) was also significantly increased in
165 patients with mild COVID-19 when compared to the patients who tested negative for the

166 virus (ANOVA test F: 4.024, $p= 0.009$ **, **Figure 2d**). All data was corrected for age and
167 sex.

168 The ratio of several metabolites was used to further investigate the induction of the
169 kynurenine pathway. The KYN/TRP ratio was quantified to determine the induction of the
170 kynurenine pathway. When both groups were compared, COVID-19 patients showed
171 significantly increased levels of the induction of the kynurenine pathway (ANOVA test F:
172 6.377, $p< 0.001$ ***, **Figure 3**). The QUIN/TRP ratio, which has been previously identified
173 as a biomarker for neurological diseases (26), was also analyzed. COVID-19 positive
174 cases showed a statistically significant increase in this ratio when compared to the non-
175 COVID-19 patients (ANOVA test F: 5.837, $p<0.001$ ***, **Figure 3**). Another neurotoxic
176 ratio that was measured was QUIN/KYNA. In this study, COVID-19 positive patients
177 presented significantly higher ratios when compared to the control group (ANOVA test F:
178 2.847, $p= 0.040$ *, **Figure 3**). All data was corrected for age and sex.

179 ***Correlation between neurotoxic metabolites of the kynurenine pathway and pro-*** 180 ***inflammatory cytokines***

181 Previous research has shown the relationship between inflammation and the kynurenine
182 pathway activity. Therefore, we subsequently investigated whether the levels of
183 kynurenine metabolites and inflammatory cytokines were correlated. As shown in **Figure**
184 **4**, there was a positive correlation between the levels of TNF- α and KYN (Pearson
185 correlation: 0.453; $p=0.002$ **), 3-HK (Pearson correlation: 0.527; $p<0.001$ ***) and QUIN
186 (Pearson correlation: 0.482; $p<0.001$ ***). Furthermore, a positive correlation between IL-
187 6 and both 3-HK (Pearson correlation: 0.328; $p=0.03$ *) and QUIN (data adjusted for age

188 and sex, Pearson correlation: 0.418; $p=0.005^{**}$) was also found. All data was corrected
189 for age and sex.

190 ***Increased levels of neurotoxic metabolites in COVID-19 patients with hypertension***

191

192 We then analyzed patients who presented with hypertension, a well-known risk factor for
193 severe COVID-19, and compared them with the patients that were not hypertensive in
194 both COVID-19 positive and negative patients. Regression analysis adjusted for age and
195 sex revealed that COVID-19 hypertensive patients presented evidence of higher levels
196 when compared to non-hypertensive COVID-19 patients in the following proteins: IL-2
197 (fold change 2.66, $p=0.003^{**}$), IL-6 (fold change 1.45, $p\text{-value}=0.014^*$), TNF- α (fold
198 change 1.38, $p=0.012^*$), 3-HK (fold change 1.26, $p=0.08$), and the QUIN/TRP ratio (fold
199 change 1.14, $p = 0.089$) (**Figure 5**).

200

201

202

203

204 **Discussion**

205
206 In the current study, we investigated the inflammatory and kynurenine pathway metabolite
207 signatures between mild COVID-19 cases and controls. We found increases in several
208 kynurenine pathway metabolites, such as KYN, QUIN, 3-HK and PIC, together with higher
209 levels of IL-6. Additionally, the increased levels in QUIN/TRP, QUIN/KYN, QUIN/KYNA
210 and KYN/TRP, further support a recent published study by Cihan and colleagues (23).
211 Pro-inflammatory pathway proteins, along with metabolites from the kynurenine pathway
212 were significantly increased in patients that presented with both COVID-19 and
213 hypertension when compared to COVID-19 patients that were not hypertensive. Those
214 proteins included IL-2, IL-6, TNF α , ICAM-1, VCAM-1, 3-HK, QUIN, QUIN:TRP and
215 KYN:TRP.

216
217 Kynurenine pathway metabolites are correlated with severity and predicted negative
218 outcomes of symptoms in COVID-19 patients; therefore, it is important to understand the
219 role of kynurenine metabolites in mild COVID-19 patients and long-haulers, in particular
220 those with neuropsychiatric symptoms (15). In this study, we found the levels of ICAM-1
221 and VCAM-1 to be significantly increased in patients with mild SARS-CoV-2, in particular
222 those with hypertension. Increased levels of ICAM-1 and VCAM-1 in mild and severe
223 cases of COVID-19 infection has already been reported in a small study (27), where it
224 was observed that the severity of COVID-19 disease was associated with increased
225 levels of ICAM-1 and VCAM-1. The main caveat with that study was the small number of
226 patients analyzed. Our new findings support the prior observations and link increases in
227 endothelial cell adhesion molecules to kynurenine pathway metabolites, such as IDO.

228 IDO is expressed in endothelial cells of vessel walls, and under pathological states, a
229 decrease in IDO leads to an increase in VCAM-1 (28). Therefore, understanding how the
230 kynurenine pathway is involved in inflammatory diseases and how it can alter the levels
231 of ICAM-1 and VCAM-1 will be important to understand, especially in the context of
232 COVID-19.

233
234 Lionetto et al., measured the levels of KYN and TRP in the serum of healthy patients,
235 SARS-CoV-2 negative patients, and SARS-CoV-2 positive patients (29). In SARS-CoV-2
236 positive patients, the KYN/TRP ratio was higher when compared to the negative and the
237 healthy controls (29). We also found an increase in the KYN/TRP ratio in SARS-CoV-2
238 positive patients when compared to those who tested negative. The KYN/TRP ratio is
239 usually used as an indirect measure of the activity of the IDO enzyme (30); which
240 catalyzes tryptophan. Previous research has demonstrated that IDO is regulated by IFN-
241 γ (31, 32). We observed no differences in the levels of serum IFN- γ in mild COVID-19
242 samples. However, IDO activation and gene expression has also been shown to be
243 altered by noncanonical pathways in addition to IFN- γ (33). This potentially explains the
244 increased kynurenine pathway activation that we observed in our cohort. The activation
245 of the kynurenine pathway may cause long-lasting inflammation rather than the acute
246 inflammation observed early in COVID-19. Therefore, it will be of interest to follow the
247 kynurenine metabolites as markers in patients with symptoms of long-COVID.

248
249 Together with the KYN/TRP ratio, the QUIN/TRP ratio was increased in patients with
250 COVID-19 when compared to controls. In a previous study, Drewes and colleagues

251 suggest that cerebrospinal fluid (CSF) QUIN/TRP ratio could be an early, predictive
252 marker of CNS disease (26). In simian-immunodeficient virus (SIV)-infected macaques,
253 the ratio of QUIN/TRP was significantly increased in cases that led to severe encephalitis
254 (26). Encephalitis is one of the many potential consequences of COVID-19 patients (34);
255 and the QUIN/TRP ratio could be used to determine the outcome of patients. Our data
256 show a significant increase in this ratio in COVID-19 patients, when compared to those
257 that tested negative for the virus. We also found that the ratio between QUIN/TRP was
258 also increased in hypertensive COVID-19 patients, suggesting that patients with
259 hypertension might be prone to a worse outcome.

260

261 Cihan and colleagues analyzed kynurenine pathway metabolites and inflammatory
262 cytokines and found a positive correlation between IL-6 and various metabolites from the
263 kynurenine pathway (23). Our study supports a positive correlation between IL-6 and
264 QUIN as well as between IL-6 and 3-HK. Since Cihan's study analyzed severe and ICU
265 cases of COVID-19 patients, it is possible that the lack of correlation between IL-6 and
266 other kynurenine metabolites in our study is because only mild COVID-19 cases were
267 analyzed. The correlation of IL-6 and kynurenine metabolites could also potentially be
268 used as a biomarker of disease severity.

269

270 The correlation between IL-6, IFN- γ , and TNF- α and kynurenine metabolites supports the
271 link between inflammation, SARS-CoV-2 and the kynurenine pathway. We found a
272 positive correlation between TNF- α and three metabolites: 3-HK, KYN, and QUIN. TNF-
273 α affects the kynurenine pathway in patients with schizophrenia, as a positive correlation

274 between the levels of TNF- α and KYN has been reported (35). TNF- α may accelerate the
275 formation of KYN from the catabolism of TRP (35). We did not observe differences in
276 TNF- α levels between negative and positive SARS-CoV-2 patients, however, we did find
277 a correlation between TNF- α and KYN levels, similar to what has been reported for
278 schizophrenia (35). In this study, QUIN, 3-HK and KYN were significantly increased in
279 patients with mild COVID-19. Both QUIN and 3-HK are neurotoxic metabolites and were
280 positively correlated with TNF- α and IL-6 in the case of QUIN, and TNF- α in the case of
281 3-HK, it is possible that the inflammation observed in COVID-19 patients further
282 contributes to the neuronal damage caused by the neurotoxic metabolites.
283 To summarize, we found an increase in neurotoxic metabolites of the kynurenine pathway
284 in patients with mild COVID-19. Furthermore, the neurotoxic metabolites were correlated
285 with inflammatory markers and vascular injury markers, such as TNF- α , IL-6, VCAM-1
286 and ICAM-1. We hypothesize that the activation of the neurotoxic branch of the
287 kynurenine pathway might contribute to neurological, cognitive, and psychiatric
288 symptoms experienced in COVID-19 and its aftermath. We suggest that these
289 metabolites should be studied further for their potential as biomarkers of long COVID and
290 as potential contributors to the disease mechanisms underlying long COVID.

291

292

293

294

295

296

297 **Materials and Methods**

298

299 *Blood samples*

300 Blood was drawn by venipuncture of the right or left antecubital vein. Blood was allowed
301 to clot at room temperature prior to centrifugation. Serum was aliquoted into cryovials and
302 immediately transferred to -80°C for storage until biological assays.

303

304 *Detection of tryptophan, serotonin, and kynurenine metabolites*

305 Serum samples were mixed with extraction solution, briefly vortexed and centrifuged. The
306 supernatant, which contains the metabolites of interest was removed and dried under
307 reduced pressure conditions for ninety minutes in a GeneVac EZ-2 Plus speedvac (SP
308 Scientific, Warminster,PA). Dried down extracts were then resuspended in 0.1% formic
309 acid in Milli-Q water, once resuspended samples were centrifuged through a COSTAR
310 Spin-X 0.22-um filter tube and transferred to an amber vial containing a glass insert.

311

312 *Quantification of kynurenine metabolites*

313 Kynurenine pathway metabolites (KYN, KYNA, 3-HK, QUIN, PIC, NTA, NIC, AA), TRP
314 and serotonin were quantified using reverse phase ultra-high-performance liquid
315 chromatography (UHPLC) coupled to a triple quadrupole mass spectrometer (1290
316 Infinity II LC System, 6470 Triple quadrupole, Agilent Technologies, Santa Clara, CA).
317 Five-microliters of samples were injected onto a Vanguard HSS T3 Pre-column that was
318 connected to an Acquity HSS T3 analytical column. Elution conditions used a combination
319 of Solvent A (0.1% formic acid in LC/MS grade Water) and Solvent B (0.1% formic acid

320 in 90% LC/MS grade acetonitrile) at a flow rate of 0.4mL/min. Agilent Masshunter
321 Quantitative Analysis Software (v9.0, Agilent) was used to analyze and export data.
322 Intra-assay coefficients of variability (CV) for plasma analytes: TRP 4.1%, KYN 2.5%,
323 KYNA 1.6%, 3-HK 5.0%, QUIN 2.8%, PIC 3.3%, NTA 1.6%, NIC 5.4%, AA 8.4% and 5-
324 HT 2.2%.
325 Inter-assay CVs: TRP 4.8%, KYN 1.8%, KYNA 1.5%, 3-HK 4.9%, QUIN 1.8%, PIC 1.9%,
326 NTA 1.8%, NIC 6.5%, AA 7.2% and 5-HT 4.9%.
327 Lower limits of detection (LLOD) were found to be as follows: TRP 36.6 nM, KYN 2.2 nM,
328 KYNA 0.16 nM, 3-HK 0.29 nM, QUIN 4.15 nM, PIC 0.63 nM, NTA 0.98 nM, NIC 0.07 nM,
329 AA 0.98 nM and 5-HT 0.73 nM.

330

331 *Quantification of cytokines and alpha-synuclein*

332 Three Meso Scale Discovery (MSD) multiplex kits (Meso Scale Diagnostics LLC,
333 Rockville, MD) were read using a MESO QuickPlex SQ 120 plate reader. Samples were
334 run in duplicate according to the manufacturer's instructions and sample concentrations
335 were generated through MSD Discovery Workbench 4.0 software. Samples below the
336 average LLOD were denoted as the average LLOD across plates. For α -synuclein, the
337 U-PLEX human α -synuclein kit was used. Samples were diluted 1:8 with sample diluent
338 and generated an inter-plate CV of 3%, an average intra-assay CV of 5.2%, and the LLOD
339 of 0.876 pg/mL.

340

341 Using the MSD V-PLEX human vascular injury II kit, we quantified C-reactive protein
342 (CRP), serum amyloid A (SAA), ICAM-1, and VCAM-1. Samples were diluted 1:1000 with

343 manufacturer's diluent reagent. The inter-plate CV was 10.3% (CRP: 8.3%, SAA: 9.7%,
344 ICAM-1: 15.2%, VCAM-1: 8.1 %), average intra-assay CV 5.6% (CRP 4.2%, SAA 6.5%,
345 ICAM-1 6.6%, and VCAM-1 5.2%), the LLOD were 1.077pg/mL CRP, 12.839 pg/mL SAA,
346 1.037 pg/mL ICAM-1, and 6.618 pg/mL VCAM-1.

347

348 The MSD V-PLEX human proinflammatory I kit was used to determine the level of IFN- γ ,
349 interleukin (IL)-10, IL-12p70, IL-13, IL-1 β , IL-2, IL-4, IL-6, IL-8, and tumor necrosis factor
350 alpha (TNF- α). Samples were diluted 1:1 with sample diluent. Inter-plate CV were
351 calculated (**see Supplementary Table 1**), and the LLOD was IFN- γ : 0.087 pg/mL, IL-10:
352 0.025 pg/mL, IL-12p70: 0.0385 pg/mL, IL-13: 0.209 pg/mL, IL-1 β : 0.032 pg/mL, IL-2:
353 0.024 pg/mL, IL-4: 0.004 pg/mL, IL-6: 0.045 pg/mL, IL-8: 0.017 pg/mL, and TNF- α : 0.049
354 pg/mL.

355

356 *Quantification of Neopterin and S100B*

357 Neopterin ELISA kits were purchased from IBL America (Immuno-Biological Laboratories
358 Inc., Minneapolis, MN). Undiluted serum samples were used following the manufacturer's
359 protocol. S100B ELISA kits were purchased from Millipore (EMD Millipore, St. Louis, MO)
360 and samples were diluted 1:1. Plates were read using a Tecan Infinite M200 Pro plate
361 reader (Tecan Group Ltd, Männedorf, Switzerland). Sample concentrations were
362 generated using a 4 Parameter Logistic Curve Calculator (AAT Bioquest, "Quest Graph
363 Four Parameter Logistic (4PL) Curve Calculator" 15 Jul. 2021,
364 [https://www.aatbio.com/tools/four-parameter-logistic-4pl-curve-regression-online-
calculator](https://www.aatbio.com/tools/four-parameter-logistic-4pl-curve-regression-online-calculator)). The average inter-plate CV for Neopterin was 12.1%, the average intra-assay

366 CV was 2.2%, and the LLOD given by the manufacturer is 0.177 ng/mL. For S100B the
367 average inter-plate CV was 5.0%, the average intra-assay CV was 1.9%, and the LLOD
368 was 2.7 pg/mL as specified by the manufacturer.

369

370 *Statistical analysis*

371 Models were adjusted for age and sex in all instances. Robust linear regressions to
372 assess differences between PCR+ individuals with and without hypertension were
373 analyzed via R v 4.1.0 (<https://cran.r-project.org/>). Correlation analyses and ANOVAs
374 were done with SPSS Statistics (version 28.0.1.0). Graphs were generated using
375 GraphPad Prism version 9.0374 (GraphPad Software, La Jolla, CA). For all tests,
376 statistical significance was considered as $p < 0.05$ and weak evidence as $0.05 < p < 0.1$.

377

378 *Study approval*

379 This study utilized a subset of samples from the Beaumont Health Large-Scale
380 Automated Serologic Testing for COVID-19 study (36) and was approved by the
381 Institutional Review Board (IRB) at the Beaumont Research Institute Detroit, Michigan,
382 USA (2021-110). The final cohort consisted of 150 individuals (44 Mild COVID-19 cases
383 and 106 controls) randomly selected from the registry. Individuals testing positive for
384 SARS-CoV-2 in a qPCR test at the time of sampling were assigned “Covid19 positive”
385 whereas individuals testing negative in a qPCR test for C SARS-CoV-2 at the time of
386 blood sample were assigned “Covid19 negative” for the purpose of this study.

387

388

389

390 **Author Contributions**

391 Conceptualization, LB SFG, PB; data curation, ESM, ARB, CDC, CF, KH; formal analysis,
392 ESM, LB, SFG, PB, regression analysis with R, ZM; methodology, LB; visualization, ESM,
393 ARB; writing—original draft, ESM, ARB; writing—review and editing, SG, MXH, JAP, PB,
394 SFG, LB.

395
396 **Acknowledgements**

397
398 We would like to thank the Farmer Family Foundation for their generous contribution,
399 which allowed for this research to be conducted. Additionally, we would like to thank the
400 Van Andel Institute Metabolomics and Bioenergetics Core for providing technical
401 assistance. This project was also supported with Beaumont institutional funds as well as
402 through the Beaumont Health Foundation with philanthropic gifts provided by the
403 following: Sidney & Madeline Forbes, Nathan & Catherine Forbes, Edward C. Levy & the
404 Linda Dresner Foundation, Stephen & Bobbi Polk, Warren & Carol Ann Rose & Family,
405 Elizabeth Rose, Mickey Shapiro & Family, S. Evan & Gwen Weiner and The Hearst
406 Foundations.

407

408

409

410 **List of abbreviations**

411 3-HK: 3-HydroxyKynurenine

412 AA: Anthranilic Acid

413 BBB: Blood Brain Barrier

414 COVID-19: Coronavirus Disease (2019)

415 CI: Confidence Interval

416 CSF: Cerebrospinal Fluid

417 Glu: Glutamate

418 ICAM-1: Intercellular Adhesion Molecule 1

419 ICU: Intensive Care Unit

420 IDO: Indoleamine 2,3-Dioxygenase

421 IFN- γ : Interferon Gamma

422 IL: Interleukins

423 KYN: Kynurenine

424 KYNA: Kynurenic Acid

425 PA: Picolinic Acid

426 PCR: Polymerase Chain Reaction

427 ROS: Reactive Oxygen Species

428 S100B: S100- Calcium-Binding Protein B

429 SAA: Serum Amyloid A

430 SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

431 SIV: Simian Immunodeficient Virus

432 TNF- α : Tumor Necrosis Alpha

433 TRP: Tryptophan

434 QUIN: Quinolinic acid

435

436 **Data availability**

437 Data generated is available upon request.

438

439 **Competing interests**

440

441 P.B. has received support as a consultant from Calico Life Sciences, CureSen,
442 Enterin Inc, Idorsia Pharmaceuticals, Lundbeck A/S, AbbVie, Fujifilm-Cellular Dynamics
443 International, and Axial Therapeutics. He has received commercial support for research
444 from Lundbeck A/S and F. Hoffman-La Roche. He has ownership interests in Acousort
445 AB, Axial Therapeutics, Enterin Inc and RYNE Biotechnology. During the time that this
446 paper was written he became an employee of F. Hoffman-La Roche, although none of
447 the data were generated by this company.

448

449

450

451

452

453

454

455

456

457 **References**

- 458
- 459 1. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of
460 Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.*
461 2020;77(6):683-90. doi: 10.1001/jamaneurol.2020.1127. PubMed PMID: 32275288; PubMed
462 Central PMCID: PMC7149362.
 - 463 2. Anka AU, Tahir MI, Abubakar SD, Alsabbagh M, Zian Z, Hamedifar H, et al. Coronavirus
464 disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and
465 management. *Scand J Immunol.* 2021;93(4):e12998. Epub 20201203. doi: 10.1111/sji.12998.
466 PubMed PMID: 33190302; PubMed Central PMCID: PMC7744910.
 - 467 3. Roy D, Ghosh R, Dubey S, Dubey MJ, Benito-León J, Kanti Ray B. Neurological and
468 Neuropsychiatric Impacts of COVID-19 Pandemic. *Can J Neurol Sci.* 2021;48(1):9-24. Epub
469 20200805. doi: 10.1017/cjn.2020.173. PubMed PMID: 32753076; PubMed Central PMCID:
470 PMC7533477.
 - 471 4. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat*
472 *Med.* 2022. Epub 20220525. doi: 10.1038/s41591-022-01840-0. PubMed PMID: 35614233.
 - 473 5. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain:
474 when physiology meets pathology. *Nat Rev Neurosci.* 2012;13(7):465-77. doi: 10.1038/nrn3257.
475 PubMed PMID: 22678511; PubMed Central PMCID: PMC3681811.
 - 476 6. Lugo-Huitrón R, Blanco-Ayala T, Ugalde-Muñiz P, Carrillo-Mora P, Pedraza-Chaverri J,
477 Silva-Adaya D, et al. On the antioxidant properties of kynurenic acid: free radical scavenging
478 activity and inhibition of oxidative stress. *Neurotoxicol Teratol.* 2011;33(5):538-47. Epub
479 20110713. doi: 10.1016/j.ntt.2011.07.002. PubMed PMID: 21763768.
 - 480 7. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The
481 brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-
482 alpha7 nicotinic receptor expression: physiopathological implications. *J Neurosci.*
483 2001;21(19):7463-73. doi: 10.1523/jneurosci.21-19-07463.2001. PubMed PMID: 11567036;
484 PubMed Central PMCID: PMC6762893.
 - 485 8. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. *Pharmacol Rev.*
486 1993;45(3):309-79. PubMed PMID: 8248282.
 - 487 9. Wang Q, Liu D, Song P, Zou MH. Tryptophan-kynurenine pathway is dysregulated in
488 inflammation, and immune activation. *Front Biosci (Landmark Ed).* 2015;20(7):1116-43. Epub
489 20150601. doi: 10.2741/4363. PubMed PMID: 25961549; PubMed Central PMCID:
490 PMC4911177.
 - 491 10. Ishii T, Iwahashi H, Sugata R, Kido R. Formation of hydroxanthommatin-derived radical
492 in the oxidation of 3-hydroxykynurenine. *Arch Biochem Biophys.* 1992;294(2):616-22. doi:
493 10.1016/0003-9861(92)90733-d. PubMed PMID: 1314547.
 - 494 11. Wang Q, Zhang M, Ding Y, Wang Q, Zhang W, Song P, et al. Activation of NAD(P)H
495 oxidase by tryptophan-derived 3-hydroxykynurenine accelerates endothelial apoptosis and
496 dysfunction in vivo. *Circ Res.* 2014;114(3):480-92. Epub 20131126. doi:
497 10.1161/circresaha.114.302113. PubMed PMID: 24281189; PubMed Central PMCID:
498 PMC4104160.
 - 499 12. Skorobogatov K, De Picker L, Verkerk R, Coppens V, Leboyer M, Müller N, et al. Brain
500 Versus Blood: A Systematic Review on the Concordance Between Peripheral and Central
501 Kynurenine Pathway Measures in Psychiatric Disorders. *Front Immunol.* 2021;12:716980. Epub

- 502 20210923. doi: 10.3389/fimmu.2021.716980. PubMed PMID: 34630391; PubMed Central
503 PMCID: PMC8495160.
- 504 13. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, et al. Kynurenine
505 pathway metabolism in human astrocytes: a paradox for neuronal protection. *J Neurochem.*
506 2001;78(4):842-53. doi: 10.1046/j.1471-4159.2001.00498.x. PubMed PMID: 11520905.
- 507 14. Agudelo LZ, Femenía T, Orhan F, Porsmyr-Palmertz M, Goiny M, Martinez-Redondo V,
508 et al. Skeletal muscle PGC-1 α modulates kynurenine metabolism and mediates resilience to
509 stress-induced depression. *Cell.* 2014;159(1):33-45. doi: 10.1016/j.cell.2014.07.051. PubMed
510 PMID: 25259918.
- 511 15. Oxenkrug G, Summergrad P. Peripheral kynurenines as biomarkers and targets for
512 prevention and treatment of psychiatric conditions associated with SARS-CoV-2 infection.
513 *Personalized Medicine in Psychiatry.* 2021;29-30:100088. doi:
514 <https://doi.org/10.1016/j.pmip.2021.100088>.
- 515 16. Lembas A, Zawartko K, Sapuła M, Mięka T, Kozłowska J, Wiercińska-Drapała A.
516 VCAM-1 as a Biomarker of Endothelial Function among HIV-Infected Patients Receiving and
517 Not Receiving Antiretroviral Therapy. *Viruses.* 2022;14(3). Epub 20220311. doi:
518 10.3390/v14030578. PubMed PMID: 35336985; PubMed Central PMCID: PMC8955345.
- 519 17. Chen YH, Lightman S, Eskandarpour M, Calder VL. Adhesion Molecule Targeted Therapy
520 for Non-Infectious Uveitis. *Int J Mol Sci.* 2022;23(1). Epub 20220103. doi:
521 10.3390/ijms23010503. PubMed PMID: 35008929; PubMed Central PMCID: PMC8745221.
- 522 18. Kang L, Kim M, Lee YM. Expression of ICAM-1 in Blood Vascular Endothelium and
523 Tissues in Human Premalignant Lesion and Gastric/Hepatocellular Carcinomas. *Korean J*
524 *Gastroenterol.* 2022;79(4):170-6. doi: 10.4166/kjg.2022.008. PubMed PMID: 35473775.
- 525 19. Bui TM, Wiesolek HL, Sumagin R. ICAM-1: A master regulator of cellular responses in
526 inflammation, injury resolution, and tumorigenesis. *J Leukoc Biol.* 2020;108(3):787-99. Epub
527 20200317. doi: 10.1002/jlb.2mr0220-549r. PubMed PMID: 32182390; PubMed Central PMCID:
528 PMC7977775.
- 529 20. Hyun YM, Lefort CT, Kim M. Leukocyte integrins and their ligand interactions. *Immunol*
530 *Res.* 2009;45(2-3):195-208. Epub 20090129. doi: 10.1007/s12026-009-8101-1. PubMed PMID:
531 19184539; PubMed Central PMCID: PMC2990789.
- 532 21. Ramos TN, Bullard DC, Barnum SR. ICAM-1: isoforms and phenotypes. *J Immunol.*
533 2014;192(10):4469-74. doi: 10.4049/jimmunol.1400135. PubMed PMID: 24795464; PubMed
534 Central PMCID: PMC4015451.
- 535 22. Bohnacker S, Hartung F, Henkel F, Quaranta A, Kolmert J, Priller A, et al. Correction to:
536 Mild COVID-19 imprints a long-term inflammatory eicosanoid- and chemokine memory in
537 monocyte-derived macrophages. *Mucosal Immunol.* 2022;1. Epub 20220513. doi:
538 10.1038/s41385-022-00526-7. PubMed PMID: 35562559; PubMed Central PMCID:
539 PMC9098895.
- 540 23. Cihan M, Doğan Ö, Ceran Serdar C, Altunçekiç Yıldırım A, Kurt C, Serdar MA.
541 Kynurenine pathway in Coronavirus disease (COVID-19): Potential role in prognosis. *J Clin Lab*
542 *Anal.* 2022;36(3):e24257. Epub 20220129. doi: 10.1002/jcla.24257. PubMed PMID: 35092710;
543 PubMed Central PMCID: PMC8906035.
- 544 24. Holtze M, Asp L, Schwieler L, Engberg G, Karlsson H. Induction of the kynurenine
545 pathway by neurotropic influenza A virus infection. *J Neurosci Res.* 2008;86(16):3674-83. doi:
546 10.1002/jnr.21799. PubMed PMID: 18655201.

- 547 25. Wickström R, Fowler Å, Gojny M, Millischer V, Ygberg S, Schwieler L. The Kynurenine
548 Pathway is Differentially Activated in Children with Lyme Disease and Tick-Borne Encephalitis.
549 *Microorganisms*. 2021;9(2). Epub 20210204. doi: 10.3390/microorganisms9020322. PubMed
550 PMID: 33557172; PubMed Central PMCID: PMC7913947.
- 551 26. Drewes JL, Meulendyke KA, Liao Z, Witwer KW, Gama L, Ubaida-Mohien C, et al.
552 Quinolinic acid/tryptophan ratios predict neurological disease in SIV-infected macaques and
553 remain elevated in the brain under cART. *J Neurovirol*. 2015;21(4):449-63. Epub 20150317. doi:
554 10.1007/s13365-015-0334-2. PubMed PMID: 25776527; PubMed Central PMCID:
555 PMC4512924.
- 556 27. Tong M, Jiang Y, Xia D, Xiong Y, Zheng Q, Chen F, et al. Elevated Expression of Serum
557 Endothelial Cell Adhesion Molecules in COVID-19 Patients. *J Infect Dis*. 2020;222(6):894-8. doi:
558 10.1093/infdis/jiaa349. PubMed PMID: 32582936; PubMed Central PMCID: PMC7337874.
- 559 28. Kiluk M, Lewkowicz J, Pawlak D, Tankiewicz-Kwedlo A. Crosstalk between Tryptophan
560 Metabolism via Kynurenine Pathway and Carbohydrate Metabolism in the Context of Cardio-
561 Metabolic Risk-Review. *J Clin Med*. 2021;10(11). Epub 20210604. doi: 10.3390/jcm10112484.
562 PubMed PMID: 34199713; PubMed Central PMCID: PMC8199979.
- 563 29. Lionetto L, Ulivieri M, Capi M, De Bernardini D, Fazio F, Petrucca A, et al. Increased
564 kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An
565 observational cohort study. *Biochim Biophys Acta Mol Basis Dis*. 2021;1867(3):166042. Epub
566 20201216. doi: 10.1016/j.bbadis.2020.166042. PubMed PMID: 33338598; PubMed Central
567 PMCID: PMC7834629.
- 568 30. Badawy AA-B, Guillemin G. The Plasma [Kynurenine]/[Tryptophan] Ratio and
569 Indoleamine 2,3-Dioxygenase: Time for Appraisal. *International Journal of Tryptophan Research*.
570 2019;12:1178646919868978. doi: 10.1177/1178646919868978. PubMed PMID: 31488951.
- 571 31. Badawy AA. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional
572 Aspects. *Int J Tryptophan Res*. 2017;10:1178646917691938. Epub 20170315. doi:
573 10.1177/1178646917691938. PubMed PMID: 28469468; PubMed Central PMCID:
574 PMC5398323.
- 575 32. Sarkar SA, Wong R, Hackl SI, Moua O, Gill RG, Wiseman A, et al. Induction of
576 indoleamine 2,3-dioxygenase by interferon-gamma in human islets. *Diabetes*. 2007;56(1):72-9.
577 doi: 10.2337/db06-0617. PubMed PMID: 17192467.
- 578 33. Liang Y, Yu Z, Song Y, Wang T, Xiao B. Indoleamine 2,3-Dioxygenase Activation by
579 Interferon Gamma in Vascular Endothelial Rat Cells Requires Noncanonical NF-κB Signaling.
580 *Transplant Proc*. 2019;51(6):2141-5. Epub 20190712. doi: 10.1016/j.transproceed.2019.03.043.
581 PubMed PMID: 31307771.
- 582 34. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological
583 associations of COVID-19. *Lancet Neurol*. 2020;19(9):767-83. Epub 20200702. doi:
584 10.1016/s1474-4422(20)30221-0. PubMed PMID: 32622375; PubMed Central PMCID:
585 PMC7332267.
- 586 35. Okamoto N, Natsuyama T, Igata R, Konishi Y, Tesen H, Ikenouchi A, et al. Associations
587 Between the Kynurenine Pathway, Proinflammatory Cytokines, and Brain-Derived Neurotrophic
588 Factor in Hospitalized Patients With Chronic Schizophrenia: A Preliminary Study. *Front*
589 *Psychiatry*. 2021;12:696059. Epub 20210728. doi: 10.3389/fpsy.2021.696059. PubMed PMID:
590 34393855; PubMed Central PMCID: PMC8357143.
- 591 36. Sims MD, Maine GN, Childers KL, Podolsky RH, Voss DR, Berkiw-Scenna N, et al.
592 Coronavirus Disease 2019 (COVID-19) Seropositivity and Asymptomatic Rates in Healthcare

593 Workers Are Associated with Job Function and Masking. Clin Infect Dis. 2021;73(Suppl 2):S154-
594 s62. doi: 10.1093/cid/ciaa1684. PubMed PMID: 33150375; PubMed Central PMCID:
595 PMC7665441.

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616


617

618 **Table 1. Demographics of the patients included in the current study**

Mild SARS-CoV-2 Demographics		
	SARS-CoV-2 Negative (n = 106)	SARS-CoV-2 Positive (n = 44)
Age (Mean + SD)	45.65 + 13.39	44.18 + 13.12
Sex F (%)	47 (44.3%)	25 (56.8%)
Race n (%)		
Asian	8 (7.5%)	7 (15.9%)
Black/African	5 (4.7%)	0 (0%)
White/Caucasian	84 (79.2%)	35 (79.5%)
Other	4 (3.8%)	2 (4.5%)
No Answer	5 (4.7%)	0 (0%)


619
620 SD: Standard Deviation
621 F: female
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649

650 **Figures:**
651
652




653 **Figure 1. Significantly higher levels IL-6 in patients with mild COVID-19 when**
654 **compared to controls. a)** Significantly higher levels of IL-6 were found in patients with
655 COVID-19 when compared to the negative controls (data adjusted for age and sex,
656 ANOVA test F: 5.260, p=0.002 **). **b)** No differences were found in the level of TNF- α
657 between the two groups (data adjusted for age and sex, ANOVA test F: 2.347, p= 0.075
658 ns). Graphs are represented by median with 95% of confidence interval (CI).
659

660
661
662
663
664
665
666
667
668
669
670
671
672
673
674




675
676
677
678
679
680
681
682

Figure 2. Significantly higher levels of serum ICAM-1, VCAM-1, and neopterin in patients with COVID-19. When the levels of all three proteins were analyzed, patients with COVID-19 presented significantly higher levels of **a)** ICAM-1 (data adjusted for age and sex, ANOVA test F: 5.823, $p < 0.001$ ***), **b)** VCAM-1 (data adjusted for age and sex, ANOVA test F: 3.307, $p = 0.022$ *), and **c)** neopterin (data adjusted for age and sex, ANOVA test F: 3.309, $p = 0.022$ *). Graphs are represented by median with 95% of confidence interval (CI).



683
 684 **Figure 3. The kynurenine pathway is altered in patients with mild COVID-19, who present**
 685 **increased levels of neurotoxic metabolites.** Significantly increased levels of kynurenine (data
 686 adjusted for age and sex, ANOVA test F: 11.195, $p < 0.001$ ***), 3-hydroxykynurenine (data
 687 adjusted for age and sex, ANOVA test F: 3.390, $p = 0.009$ **), anthranilic acid (data adjusted for
 688 age and sex, ANOVA test F: 4.024, $p = 0.009$ **), and quinolinic acid (data adjusted for age and
 689 sex, ANOVA test F: 8.492, $p < 0.001$ ***) were found in patients with mild COVID-19 when
 690 compared to controls. When the ratio of the metabolites was analyzed, significantly increased
 691 levels of KYN/TRP (data adjusted for age and sex, ANOVA test F: 6.377, $p < 0.001$ ***) and
 692 QUIN/TRP (data adjusted for age and sex, ANOVA test F: 5.837, $p < 0.001$ ***), as well as
 693 QUIN/KYNA (data adjusted for age and sex, ANOVA test F: 2.847, $p = 0.040$ *) were found in
 694 patients with COVID-19. Graphs show the median with 95% of CI. Abbreviations: IDO,
 695 Indoleamine 2,3-dioxygenase; TDO, Tryptophan 2,3-dioxygenase; KATs, Kynurenine
 696 aminotransferase; KYNA, kynurenic acid; KMO, Kynurenine 3-monooxygenase; AA, anthranilic
 697 acid; 3-HK, 3-hydroxykynurenine; KYNU, Kynureninase; 3-HAA, 3-hydroxyanthranilic acid;
 698 3HAO, 3-hydroxyanthranilate oxidase; ACMSD, Aminocarboxymuconate-semialdehyde
 699 decarboxylase, and NAD, Nicotinamide adenine dinucleotide.

700



701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722


723

724

725

726

Figure 4. There is correlation between inflammatory cytokines and metabolites of the kynurenine pathway in patients with mild COVID-19. Patients with mild COVID-19 present a positive correlation between TNF- α and kynurenine (data adjusted for age and sex, Pearson R: 0.4512; p=0.0021 **), TNF- α and 3-hydroxykynurenine (data adjusted for age and sex, Pearson R: 0.4567; p=0.0018 **), TNF- α and quinolinic acid (data adjusted for age and sex, Pearson R: 0.4812; p=0.0009 ***), IL-6 and 3-hydroxykynurenine (data adjusted for age and sex, Pearson R: 0.3252, p=0.0312 *) and between IL-6 and quinolinic acid (data adjusted for age and sex, Pearson R: 0.4161, p=0.0050 **).



727
728
729
730
731
732
733
734
735
736
737
738
739
740
741

Figure 5. Increased metabolites and ratio in COVID-19 positive hypertensive patients when compared to non-hypertensive COVID-19 patients. Higher levels of IL-2 (fold change 2.66, $p=0.003^{**}$), IL-6 (fold change 1.45, $p\text{-value}=0.014^*$), and TNF- α (fold change 1.38, $p=0.012^*$) in COVID-19 hypertensive patients when compared to COVID-19 non-hypertensive patients. Weak evidence of increased levels in 3-HK (fold change 1.26, $p=0.08^{\circ}$), and the QUIN/TRP ratio (fold change 1.14, $p = 0.089^{\circ}$). Graphs are represented by median with 95% of confidence interval (CI).